Cargando…
Long-term complete remission with belinostat in a patient with chemotherapy refractory peripheral t-cell lymphoma
Peripheral T/NK-cell lymphomas (PTCL) are rare malignancies with a poor prognosis. Due to the lack of randomised studies, standard therapy has not been established. First-line treatment with anthracycline-based polychemotherapy followed by consolidation with high-dose therapy and autologous stem cel...
Autores principales: | Reimer, Peter, Chawla, Shanta |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3846498/ https://www.ncbi.nlm.nih.gov/pubmed/24020452 http://dx.doi.org/10.1186/1756-8722-6-69 |
Ejemplares similares
-
Belinostat for Relapsed or Refractory Peripheral T-Cell Lymphoma
por: Hood, Katelyn, et al.
Publicado: (2016) -
New developments in the treatment of peripheral T-cell lymphoma – role of Belinostat
por: Reimer, Peter
Publicado: (2015) -
Profile of belinostat for the treatment of relapsed or refractory peripheral T-cell lymphoma
por: Bodiford, Andrew, et al.
Publicado: (2014) -
Complete hematologic response after belinostat treatment and allogeneic stem cell transplantation for multiple relapsed/refractory angioimmunoblastic T‐cell lymphoma: A case report
por: Camus, Vincent, et al.
Publicado: (2023) -
Hematologic toxicity is rare in relapsed patients treated with belinostat: a systematic review of belinostat toxicity and safety in peripheral T-cell lymphomas
por: Allen, Pamela B, et al.
Publicado: (2018)